Outstanding Poster Presentation Awards


About the Award

The top poster presentations from each of the three poster sessions that occur during the ASGCT Annual Meeting are awarded Outstanding Poster Presentation Awards. Awardees are honored through notification to all meeting attendees and receive a special certificate for their contributions 

Criteria and Selection

Any ASGCT Member or Associate Member who submits an abstract to the Annual Meeting is eligible to receive the award. For more information, review the abstract submission guidelines coming soon.

2021 Recipients

Marco Alessandrini
Development of Anti-CD19 Chimeric Antigen Receptor T-Cells with Immune Checkpoint Silencing

Robyn Bell
Assessment of F/HN Pseudotyped Lentiviral Vector Following Intravenous Delivery to Mice

Máté Borsos
Simultaneous Detection of AAV Genome, Transcript, and Protein Localization in Intact Cells and Tissues at High Resolution

Qian Chen
AAV9 Capsid-Anti-AAV9 Antibody Immune Complexes Promote Complement Activation and Cytokine Release In Vitro

Beatrice Cianciotti
LAG-3, Tim-3 or 2B4 Disruption Differentially Regulate the Anti-Tumor Response of TCR Gene-Edited Human Memory Stem T Cells

Agnieszka Czechowicz
Gene Therapy for Fanconi Anemia [Group A]: Preliminary Results of Ongoing RP-L102 Clinical Trials

Brianna Davey
Anti-CAR Antibody Detected after Infusion of Autologous CD4-MBL-CAR/CXCR5 CAR T Cells in SIV-Infected Rhesus Macaques

Michael Florea
High Efficiency Purification of Multiple AAV Serotypes Using AAVX Column Chromatography

Courtney Garrett
Treatment of Feline GM1 Gangliosidosis by Cerebrospinal Fluid Delivery of AAV9 or AAVrh10

Daniel Gibbs
Novel RNA-Targeting Gene Therapy Approach for Usher’s Syndrome Type II Retinitis Pigmentosa

Veronica Gough
Adenine Base Editing to Modulate mRNA Splicing as a Therapeutic Strategy for Duchenne Muscular Dystrophy

Firas Hamdan
Synergestic Tumor-Killing Effect by Cross-Hybrid IgGA Fc

Jenna Harris
Enabling Targeted Cargo Delivery to Hematopoietic Stem and Progenitor Cells with Biomimetic Nanoparticles

Dane Hazelbaker
Rigorous Assessment of Off-Target Editing by CRISPR/Cas9 in VOR33, an Engineered Hematopoietic Stem Cell Transplant for the Treatment of Acute Myeloid Leukemia

Claudia Juarez-Molina
Gene Therapy for Autoimmune Pulmonary Alveolar Proteinosis

Sushrut Kamerkar
Engineered Exosomes Efficiently Deliver STAT6 Antisense Oligonucleotides to Tumor Associated Macrophages (TAMs) Resulting in Potent Local and Systemic Anti-Tumor Activity

Jeong-A Lim
AAV-Mediated Gene Therapy Using a Novel Dual Promoter Prevents Pullulanase-Induced Cytotoxic T Lymphocyte Response and Corrects Major Affected Tissues in GSD IIIa Mice

Anne Maguire
Intravenous AAV Gene Therapy Improves Pre- and Post-Mortem Outcomes in a Feline Model of Sandhoff Disease

Ana Moreno
Long-Lasting Analgesia via Targeted In Situ Repression of Nav1.7

Christopher Nguyen
Expression of AAV Rep78 and Rep52 from Distal Baculovirus loci for Production of Gene Therapy Vectors: Proof-of-Concept and Initial Optimization

Jennifer Noel
Rod-Derived Cone Viability Factor Provides Trophic Support for Cone Photoreceptors in a Pig Model of Retinitis Pigmentosa

Yijia Pan
Temporal Gene Regulation of T Cell Enhancers by Locus Targeted Engineering Enables Cytokine Autonomy and Augments Anti-Tumor Efficacy of iPSC Derived Off-the-Shelf CAR-T Therapy

Angela Papalamprou
Directing Stepwise iPSC MSC Differentiation into iTenocytes Using Combined Transcription Factor Overexpression and Cyclic Loading in 2D Bioreactor

Adrian Pickar-Oliver
Development of AAV-Based CRISPR/Cas9 Therapies for Correcting Duchenne Muscular Dystrophy by Targeted Genomic Integration

Françoise Piguet
Intravenous Gene Therapy Apporach for Metachromatic Leukodystrophy

Maximillian Richter
P-BCMA-ALLO1 — A Fully Allogeneic Stem Cell Memory T Cell (T<sub>SCM</sub>) CAR-T Therapy Targeting BCMA for the Treatment of Multiple Myeloma Shows Potent Anti-Tumor Activity

Federico Rossari
Tumor Macrophage-Mediated Cytokine Gene Delivery Improves Trafficking and Anti-Tumor Activity of CAR T Cells against Glioblastoma

Krystal Sandza
Ultra-Sensitive AAV Capsid Detection by Immunocapture-Based Quantitative Polymerase Chain Reaction Following Factor VIII Gene Transfer

Pauline Schmit
High Throughput Phenotype-to-Phylogeny Mapping Identifies AAV Capsid Residues Involved in Neutralization by Human Sera

Nina Timberlake
Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer Non-Genotoxic Stem Cell Transplant Conditioning

Jennifer Waldo
Use of a Split AAV Delivery Platform for the Evaluation of dxCas9 for Allele-Specific Silencing in Huntington’s Disease

Eric Walton
A CRISPRa Screen Identifies Transcription Factors That Can Silence or Activate rAAV Genomes

Adrian Westhaus
AAV Capsid Development in Primary Human Retinal Explants

2021

ASGCT Policy Summit

September 22-24, 2021

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.